Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 1;26(3):bbaf237.
doi: 10.1093/bib/bbaf237.

Advances and critical aspects in cancer treatment development using digital twins

Rym Bouriga  1 , Caroline Bailleux  1 , Jocelyn Gal  2 , Emmanuel Chamorey  2 , Baharia Mograbi  3 , Jean-Michel Hannoun-Levi  4 , Gerard Milano  5
Affiliations
Review

Advances and critical aspects in cancer treatment development using digital twins

Rym Bouriga et al. Brief Bioinform. .

Abstract

The emergence of digital twins (DTs) in the arena of anticancer treatment echoes the transformative impact of artificial intelligence in drug development. DTs provide dynamic, accessible platforms that may accurately replicate patient and tumor characteristics. The potential of DTs in clinical investigation is particularly compelling. By comparing data from virtual trials with conventional trial results, medical teams can significantly enhance the reliability of their studies. Moreover, a significant breakthrough in clinical research is the ability of DT to augment patient data during ongoing trials, enabling adaptive trial designs and more robust statistical analyses to be performed even with limited patient populations. The development of DTs faces however several technical and methodological challenges. These include their tendency to produce unreliable predictions, non-factual information, reasoning errors, systematic biases, and a lack of interpretability. Future research in this field should focus on an interdisciplinary approach that brings together experts from diverse fields, including mathematicians, biologists, and physicians. This collaborative strategy promises to unlock new frontiers in personalized cancer treatment and medical methodologies.

Keywords: artificial intelligence; clinical trials; digital twins; drug discovery; oncology.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
Digital twins in cancer treatment development: SWOT analysis.
See this image and copyright information in PMC

References

    1. Wong H-H, Jessup A, Sertkaya A. et al. Examination of Clinical Trial Costs and Barriers for Drug Development Final. Office of the Assistant Secretary for Planning and Evaluation, US Department of Health & Human Services, 2014. 1–92.
    1. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 2016;47:20–33. 10.1016/j.jhealeco.2016.01.012 - DOI - PubMed
    1. Moore TJ, Heyward J, Anderson G. et al. Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study. BMJ Open 2020;10:e038863. 10.1136/bmjopen-2020-038863 - DOI - PMC - PubMed
    1. Yankeelov TE, Hormuth DA, Lima EABF. et al. Designing clinical trials for patients who are not average. iScience 2024;27:108589. 10.1016/j.isci.2023.108589 - DOI - PMC - PubMed
    1. Gal J, Milano G, Ferrero JM. et al. Optimizing drug development in oncology by clinical trial simulation: why and how? Brief Bioinform 2018;19:1203–17. 10.1093/bib/bbx055 - DOI - PubMed